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Abstract: Raloxifene, a member of the class of selective estrogen receptor modulators (SERM), reproduces the beneficial 
effects of estrogens on the skeletal systems, without the negative effects estrogens on breast and endometrium. 
This is a review article summarizing its mechanism, effects on bone and its applicability in traumatology clinical practice. 
In postmenopausal osteoporosis, this drug has been proven to decrease accelerated bone turnover, increase bone mineral 
density (BMD),
 and to structurally recover bone, decreasing the risk of vertebral fractures and the risk of non-vertebral 
fractures in patients with previous, severe vertebral fractures. Moreover, raloxifene appears to lower the risk of invasive 
breast cancer. Raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis. 
We can therefore conclude that raloxifene would be efficacious in the prevention and treatment of postmenopausal osteo-
porosis, while reducing the risk of breast cancer when used at the indicated dose of 60 mg/day and with a low incidence of 
side effects. 
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INTRODUCTION 
  Postmenopausal osteoporosis is currently an important 
public health issue due to its widespread prevalence and the 
high socio-economic and healthcare impact it entails [1], 
which justifies the establishment of pharmacological and 
non-pharmacological measures aimed at treating this disease 
and at secondary prevention of the fractures associated with 
it [2]. 
  One such pharmacological measure, hormone replace-
ment therapy (HRT), initiated at the onset of menopause, has 
been demonstrated in numerous studies to be capable of im-
proving menopause-related symptoms, while at the same 
time preventing the loss of bone mass associated with meno-
pause [2-6]. HRT thereby manages to decrease the risk of 
osteoporotic vertebral and non-vertebral fractures in women 
over the age of 60 [7]. Nevertheless, due to its side effects, 
particularly relevant among which is the potential risk of 
developing breast cancer [8, 9], the use of this type of medi-
cation should not be contemplated as first line therapy for 
osteoporosis, reserving it instead for its current indication as 
treatment of perimenopausal symptoms and always for the 
shortest time possible [1].  
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  These limitations of HRT stimulated the development of 
a series of non-hormonal compounds with a high affinity for 
estrogen receptors (ER) that are capable of reproducing the 
beneficial effects of estrogens on the skeletal system (estro-
gen agonist effect), without the negative effects on the breast 
and endometrium (estrogen antagonist effect), thanks to their 
selective binding to ER. These compounds were called Se-
lective Estrogen Receptor Modulators or SERM [10-13]. 
  Raloxifene, a second gereration benzothiophene-derived 
SERM (Fig. 1), has demonstrated this tissue specificity in 
humans and this dual action [14-16], making it an efficacious 
and safe drug in the prevention and treatment of postmeno-
pausal osteoporosis [1].
 
  In this article, we will review this drug’s mechanism of 
action, its selective effects on bone, and the determinants of 
bone strength, to then finish by analyzing its antifracture 
efficacy and applicability in clinical practice in traumatol-
ogy. 
MECHANISM OF ACTION 
  The classical model of estrogens’ mechanism of action is 
founded on the basis that estrogens, particularly estradiol 
(E2), must enter the nucleus of the target organ cells in order 
to bind there to a series of unoccupied, inactive proteins, 
called ER. These proteins, with two different isoforms, ER 
(predominantly activating) and ER (which inhibits the for-
mer), transform into active receptors with a different spatial Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability  The Open Orthopaedics Journal, 2009, Volume 3    15 
configuration (E2-ER) when they bind to E2, enabling them  
to simultaneously dimerize and subsequently interact with a 
specific sequence of DNA known as the Estrogen Respond-
ing Element (ERE) (Fig. 2, column A, level 2). A specific 
group of genes responsible for synthesizing the cell proteins 
that are in charge of triggering the estrogen effect on target 
reproductive tissues such as the uterus and the breast depend 
on ERE (Fig. 2, column A, level 3) [12-14]. 
 
Fig. (1). Raloxifene’s chemical structure. 
  Moreover, there are two specific areas in the ER known as 
activation factors (AF); the first one, or AF-1, located at the 
site of interaction with the specific DNA sequence, and the 
second one, or AF-2, located at the site where the ligand binds. 
In order for the group of genes associated with the ERE to be 
activated and hence, for the proteins associated with them to 
be synthesized (gene expression), the E2 side-chain must inter-
act with the AF-2
 region (Fig. 2, column A, level 2) [12-14]. 
  It is also known that ER do not have a single molecular 
binding site, but that they present two different domains, one 
for estrogen-type ligands and another one for antiestrogen-
type ligands and SERM. Thus, depending on the binding site 
of the ligand to the ER, different spatial structures would be 
generated which would determine, at least in part, whether 
the ligand had a pure estrogen agonist action, a partial estro-
gen agonist action, or a pure estrogen antagonist action (Fig. 
2, columns A and B, level 1) [12-14]. 
  In light of all of the afore-mentioned, it is currently be-
lieved that ER do not act in the same way in all target tissues 
and that, in all likelihood, their action depends on whether 
the alpha or beta ER subtype is predominant in the tissue in 
question, on the nature of the ligand that binds to them (es-
trogen, antiestrogen, or SERM), on the cell transcription 
machinery (ERE and AF), and on the presence or absence of 
“helper” or regulating proteins (HP) [12]. 
  Although this could account for how SERM perform 
different functions depending on the target tissue in question 
(pure agonist when interaction with ER is predominant and 
pure antagonist interaction with ER is predominant), the 
precise mechanism by which raloxifene acts is not fully un-
derstood as yet. 
  On the one hand, we know that in order for it to exert its 
effects, this medication, like E2, must cross the cytoplasmic 
membrane and the nuclear membrane in order to bind to the 
ER present in the nucleus. There, the benzothiophene ring of 
the raloxifene molecule binds to the ER with an affinity 
similar to that of E2. This bond, in addition to preventing 
access of E2 to the ER, also brings about a change in the spa-
tial configuration of the ER in charge of activating it and 
binding it to the ERE (Fig. 2, column B, level 2). However, 
unlike the intimacy with which this ring adapts to the ER, the 
basic side-chain of the molecule, which is large and inflexi-
ble, does not completely bind to it, making it “protrude” 
from the receptor area (Helix 12). This peculiarity provokes 
an alteration in the orientation of the molecule that blocks its 
possible interaction with AF-2, thereby preventing the asso-
ciated genes from being activated and their gene transcrip-
tion. In the opinion of some authors, this blockade would be 
the key to the estrogen antagonist effects of the drug on uter-
ine and breast tissues [15, 16]. 
  However, in contrast, in bone and in other non-
reproductive tissues, raloxifene bound to the ER (RLX-ER) 
and with the help of a series of HP (activating, helping, 
and/or adapting proteins) would activate a specific sequence 
of DNA known as the Raloxifene Responding Element 
(RRE). A group of genes that bring about the synthesis of 
specific cell proteins that are responsible for the estrogen 
agonist effect of the drug on these non-reproductive tissues 
would depend on this element. Thus, it would be possible to 
explain how raloxifene imitates the effect of estrogens on 
non-reproductive tissues such as bone (estrogen agonist ef-
fect)
  (Fig. 2, column B, level 3) [15, 16]. 
  However, in addition to this effect, raloxifene has dem-
onstrated that it exerts two other direct actions on bone tis-
sue. The first, which depends on the activation of its binding 
to the ligand, appears to indicate that this drug is capable of 
decreasing osteoclastic resorptive activity by up to 50%, 
interleukin-6 (IL-6) production, and up to 30% of the pro-
duction of tumor necrosis factor  (TNF-) at 6 months in 
vitro  as well as in vivo [17-19]. Both of these latter sub-
stances constitute important mediators of bone resorption. 
The second, which depends in this case on the activation of 
the RRE, suggests that raloxifene is capable of increasing the 
production of transforming growth factor 3 (TGF-3), 
thereby decreasing the number of osteoclasts as well as their 
resorptive activity (Fig. 2, column C) [20].
 
EFFECTS ON BONE AND DETERMINANTS OF 
BONE STRENGTH 
  The effects of raloxifene on bone and the determinants of 
bone strength (turnover, quantity, and quality) have been 
well studied in the last several years, not only thanks to nu-
merous experimental works carried out in animals, but also 
based on the data derived from several clinical trials con-
ducted with this drug in humans. 
Effects on Bone Turnover 
  In postmenopausal osteoporosis, bone turnover is typi-
cally accelerated, whereby in each basic multicellular unit 
(BMU) a negative bone balance occurs as a result of bone 
resorption taking place at a faster rate than bone formation. 
Consequently, at present, this determinant of bone strength is 
considered to be the fundamental physiopathological corner-
stone of the disease [21] and the process that must be con-
trolled if bone biomechanical capacity is to be recovered. 
  In both ovariectomized animals [22-24] as well as in 
postmenopausal women with [25, 26] and without osteopo-
rosis [27], raloxifene has demonstrated its ability to inhibit 
this accelerated bone resorption both short- and long-term, 
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thereby increasing bone mineral density (BMD), preserving 
bone structure, and enhancing bone strength. 
  In the double-blind, placebo-controlled clinical trial con-
ducted by Delmas et al. [27] in healthy postmenopausal 
women, raloxifene demonstrated that it significantly lowered 
bone turnover markers during the 24 months that the study 
lasted (bone-specific alkaline phosphatase by 15%, osteocal-
cin by 30%, and terminal carbonil fraction of the collagen 
type 1 C-telopeptide (CTX) by 40%). 
 
Fig. (2). Raloxifene’s mechanism of action. 
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  Likewise, but this time in postmenopausal women with 
osteoporosis, raloxifene 60 mg/day demonstrated that it was 
capable of lowering the level of all bone turnover markers by 
30 to 40% throughout the first year of treatment, a reduction 
that was maintained within premenopausal ranges during the 
entire time the studies lasted [25, 26]. The changes in the 
values of turnover markers (osteocalcin and creatinine-
corrected urinary CTX) obtained in the study by Ettinger et 
al. [25] are presented in Fig. (3). 
  In a recent study performed by Bjarnason et al. [28] in a 
subgroup of participants in the MORE Study (Multiple Out-
comes of Raloxifene Evaluation), those patients with the 
most important reductions of bone formation markers (bone-
specific alkaline phosphatase and osteocalcin) were precisely 
the ones who presented a greater decrease in the risk of ver-
tebral fracture at the 3 year endpoint; no such correlation was 
seen with bone resorption markers (urinary CTX). 
Effects on Bone Quantity (BMD: Bone Mineral Density) 
  Whereas women belonging to the control group were 
seen to loss bone mass, the group treated with raloxifene 
significantly increased BMD in the lumbar spine (2.5%), 
femoral neck (2%), and full body (1.9%) in the study con-
ducted by Delmas et al. [27]. 
  In the study performed by Ettinger et al. [25], after 36 
months of treatment, the group treated with raloxifene at a 
dose of 60 mg/day, as well as the group that received 120 
mg/day were both seen to have significantly increased BMD 
in both the lumbar spine (2.6% and 2.7%, respectively) and 
in the femoral neck (2.1% and 2.4%, respectively). 
 Cummings  et al. [29, 30] reported that that improvement 
in spine BMD underestimated the degree to which antire-
sorptive drugs reduce the risk of vertebral fractures. Thus, 
the reduction in risk of fractures resulting from these antire-
sorptive treatments (which improve bone mineral density 
between 0% and 10%) was greater than predicted from the 
improvement in spine bone mineral density. This model es-
timates, for example, that antiresorptive treatments predicted 
to reduce the risk of fractures by 20% (RR = 0.80), based on 
improvement in spine bone mineral density, have been ob-
served to reduce the risk of fractures by 45% (RR = 0.55). 
Similarly, the increase in BMD with other antirresorptive 
agents only account for 4% (calcitonin), 43% (estradiol), 
16% with alendronate, and 7-28% with risedronate [31] of 
the decreases seen in the risk of vertebral fractures with 
mencioned drugs. 
 Sarkar  et al. [32] starting with the data obtained from the 
MORE Study, examined BMD changes following 1 and 3 
years of treatment with raloxifene 60 mg/day or 120 mg/day. 
The relation between baseline BMD and the baseline to end-
point changes in BMD with the risk of new vertebral frac-
tures were analyzed in the different groups according to the 
dosis administered. As seen in other populations in the 
MORE Study, the women with the lowest baseline BMD in 
the lumbar spine and femoral neck were at greater risk for 
vertebral fracture. According the logistics regression model, 
only 4% of the reduction of the risk of vertebral fracture can 
be explain with the changes in BMD with raloxifene treat-
ment and that there is as yet no explanation for the other 
96% of the risk reduction. Authors conclude that the changes 
in BMD evaluated with raloxifene treatment are poor predic-
tors of the decrease in risk of vertebral fracture. 
  These data corroborate prior observations that the effects 
of antirresorptive medication on BMD measures by means of 
dual energy X-Ray absorptiometry are too slight as to reflect 
the reductions observed in vertebral fractures [4], and sug-
gest that other factors may also mediate in protection against 
fractures. In fact, the increase in bone turnover has been 
demonstrated to predict hip fractures in elderly women, re-
gardless of BMD values [5]. 
Effects of Raloxifene on Bone Quality 
  From a qualitative perspective and by means of quantita-
tive microrradiography of matched iliac creast biopsies taken 
at the initiation and after two years of treatment revealed that 
in patients participating in the MORE Study, both at a dosis 
of 60 mg/day as well as 120 mg/day, raloxifene was capable 
 
Fig. (3). Variation of bone turnover markers from baseline to endpoint from the MORE Study (36 months). 
 
 
 
 
 
 
 
 
 
 
 
 
M
e
d
i
a
n
 
P
e
r
c
e
n
t
a
g
e
 
C
h
a
n
g
e
f
r
o
m
 
B
a
s
e
l
i
n
e
* p<0.001 vs placebo
Placebo
RLX 60 mg/d
-10
-20
-30
-40
Months
0
0 6 12 24 36
*
Months
10
0
-10
-20
-30
-40
-50
0 6 12 24 36
Type I Collagen
C-Telopeptide / Creatinine Ratio Osteocalcin
* **
*
*
*
*
*
M
e
d
i
a
n
 
P
e
r
c
e
n
t
a
g
e
 
C
h
a
n
g
e
f
r
o
m
 
B
a
s
e
l
i
n
e
* p<0.001 vs placebo
Placebo
RLX 60 mg/d
Placebo
RLX 60 mg/d
-10
-20
-30
-40
Months
0
0 6 12 24 36
*
Months
10
0
-10
-20
-30
-40
-50
0 6 12 24 36
Type I Collagen
C-Telopeptide / Creatinine Ratio Osteocalcin
* **
*
*
*
*
*18    The Open Orthopaedics Journal, 2009, Volume 3  Caeiro et al. 
of increasing the mean degree of mineralization of bone 
(MDMB) (29% in the RLX 60 mg/day group, 8% in the 
raloxifene 120 mg/day group) with a greater rate of mineral 
heterogeneity in the treated group versus placebo. The 
MDMB profile observed in the biopsies following treatment 
with raloxifene is very similar to premenopausal physiologi-
cal bone [26]. 
  The effects of raloxifene on the histomorphometric vari-
ables were also determined by means of biopsies both prior 
to and after treatment in a six-month study in postmeno-
pausal, Caucasian patients who received a daily dose of 60 
mg of raloxifene or 0.625 mg of conjugated estrogens (CE). 
Twelve of the patients treated with raloxifene and 11 of the 
participants treated with CE underwent evaluation by bone 
biopsy during the baseline period and following six months 
of treatment. The primary efficacy parameters of bone for-
mation/bone volume index and frequency of activation 
greatly decreased with treatment with conjugated estrogens, 
as well as with raloxifene, although the differences in the 
mean percentage change were not statistically significant 
between treatment groups. In both the women treated with 
raloxifene and in those treated with CE, no signs indicative 
of bone mineralization defects or plexiform bone or me-
dullary fibrosis were seen [16]. 
  In short and given the pure estrogen agonist effect on 
bone associated with the other two parallel inhibiting effects 
of the number and activity of osteoclasts, raloxifene is able 
to lower the rate of bone resorption in postmenopausal os-
teoporosis on the one hand and, on the other, it is capable of 
reversing the negative effects that this accelerated bone turn-
over has on bone resistance determinants (bone quantity and 
quality). 
ANTIFRACTURE EFFICACY 
Vertebral Fractures 
  In the MORE Study [25], Ettinger et al. analyzed the 
efficacy of raloxifene in reducing the risk of vertebral frac-
tures in women with postmenopausal osteoporosis. This was 
a double-blind, randomized, multicenter clinical trial con-
ducted in 7705 women with postmenopausal osteoporosis 
(femoral neck BMD T scores < 2.5) aged 31 to 80 years 
(mean age of 67 years). Results demonstrated that whereas 
10.1% of the women in the control group (placebo + calcium 
and vitamin D) presented at least one new vertebral fracture, 
only 6.6% of the women treated with raloxifene 60 mg/day + 
calcium and vitamin D, and 5.4% of the women treated with 
raloxifene 120 mg/day + calcium and vitamin D presented 
said fractures. This meant that, for the treated group a sig-
nificant reduction of the relative risk (RR) of suffering this 
type of fracture = 0.60 (95% Confidence Interval (CI) = 0.5-
0.7, p < 0.01) with RR for raloxifene 60 mg/day = 0.7 (95% 
CI = 0.5-0.8) and RR for raloxifene 120 mg/day = 0.5 (95% 
CI = 0.4-0.7). This decrease in the risk of new vertebral frac-
tures was equally significant in women with osteoporosis 
and previous vertebral fractures (RR reduction of 30%) as 
well as in women with osteoporosis who had not declared 
that type of fracture at the beginning of the study (RR reduc-
tion of 50%) [33]. 
  In their re-analysis of the MORE Study data, Kanis et al. 
[34] evaluated the efficacy of raloxifene 60 mg/day in new 
vertebral fractures and new symptomatic fractures at three 
years in a subgroup of 3,204 postmenopausal women with 
osteopenia or osteoporosis without prior vertebral fractures. 
The relative risk of new vertebral fractures for the group of 
raloxifene treated patients compared to placebo was 0.53 
(95% CI = 0.32-0.88) for the group of osteopenic patients 
and 0.31 (95% CI = 0.06-0.71) for those that had osteoporo-
sis. None of the patients with osteoporosis who received 
raloxifene presented a new symptomatic vertebral fracture, 
whereas in the placebo-treated group, there were four new 
symptomatic vertebral fractures. There was no difference in 
raloxifene’s effect on vertebral fractures between osteopenic 
and osteoporotic patients (interaction p = 0.317 and 0.247, 
respectively). Authors concluded that 3 years of treatment 
with raloxifene 60 mg/day significantly lowers the risk of 
new radiographic vertebral fractures and of new sympto-
matic vertebral fractures in postmenopausal women with low 
BMD and who have not had previous vertebral fractures. 
  In a post-hoc analisys of this study, Maricic et al. [35] 
established that in a mere 12 months of treatment, 60 mg/day 
of raloxifene is capable of reducing the risk of new clinical 
vertebral fractures in the general study population by up to 
68% and by 66% in the subgroup of women who had already 
previously suffered a vertebral fracture, and who therefore 
were at greater risk for another fragility fracture. 
  These data indicate that with raloxifene, relatively low 
BMD increases are translated into significant reductions in 
the risk of vertebral fractures similar to those seen with other 
antirresorptive agents [29, 36]. 
Non-Vertebral Fractures 
  Although in the afore-mentioned MORE Study, no de-
crease in the incidence of non-vertebral fractures or hip frac-
tures was observed in the raloxifene-treated group of pa-
tients, a post hoc analysis of the same study had showed a 
relationship between the severity of prevalent vertebral frac-
tures and the risk of subsequent vertebral and nonvertebral 
fractures [36]. 
  Acording this analysis, severity of vertebral fractures at 
baseline was a stronger predictor of nonvertebral fracture 
risk than low BMD. This finding does not diminish the im-
portance of mild vertebral fractures at baseline, but severe 
prevalent vertebral fractures are probably indicative of more 
significant architectural deterioration of bone that should be 
clinically addressed. In the small subgroup of women with 
severe baseline vertebral fractures in the MORE cohort, 
raloxifene significantly decreased the risk of subsequent 
nonvertebral fractures. Nevertheless authors pointed out that, 
although this analysis is helpful in understanding the effect 
of raloxifene on vertebral and nonvertebral fractures, the 
present data do not allow for a direct comparison of nonver-
tebral fracture efficacy of raloxifene with bisphosphonates 
and do not imply that raloxifene is an alternative to bisphos-
phonates for reducing the risk of nonvertebral fractures, es-
pecially of the hip. 
Effects on Other Tissues 
  Although it was designed to evaluate the antivertebral 
fracture efficacy of raloxifene, the MORE Study demon-
strated that this SERM was capable of lowering the risk of 
breast cancer in postmenopausal women by up to 76% [37]. Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability  The Open Orthopaedics Journal, 2009, Volume 3    19 
This effect of raloxifene, perhaps having to do with its ca-
pacity to inhibit the proliferation of the human breast cancer 
cell line, MCF-7 [38], cannot a priori be extrapolated to 
young women with risk factors for breast cancer. The clini-
cal trial STAR (Study of Tamoxifen and Raloxifen) that 
compared the efficacy of tamoxifene and raloxifene in 
women at high risk for breast cancer, concluded that 
raloxifene is as efficacious as tamoxifene in reducing the risk 
of invasive breast cancer and has a lower risk of venous 
thromboembolism and cataracts, albeit after eight years of 
follow-up, there was no statistically significant difference as 
regards the risk of non-invasive breast cancer [39]. Likewise, 
in the same study the risk of developing another type of can-
cer, fractures, ischemic disease, or suffering a cerebrovascu-
lar accident was similar for both drugs. In the study carried 
out by Cummings et al. [37] previously referred to, 
raloxifene did not increase the risk of uterine cancer. 
  Several studies have demonstrated the effects of SERM 
on lipid metabolism. Specifically, it appears that raloxifene 
is capable of lowering LDL-cholesterol levels without there 
being a concomitant increase in the level of triglycerides, 
while the concentration of HDL-cholesterol increases by up 
to 15% althought there was no observed effect on end-event 
from lowering cholesterol [36, 40]. 
Side Effects 
  In general, raloxifene’s safety profile exhibits a very low 
incidence of adverse side effects [41, 42].
 Raloxifene raises 
the risk of venous thromboembolism from 1.5- to 3-fold 
[25],
 although in general, the frequency of superficial venous 
thrombophlebitis was less than 1%. Among these adverse 
effects, the most noteworthy is a 7% increase in hot flashes 
in the initial posmenopausal period [43]. Another adverse 
reaction that has been observed is leg cramps (5.5% with 
raloxifene and 1.9% with placebo in the prevention studies 
and 9.2% with raloxifene and 6.0% with placebo in treat-
ment studies). 
  Long-term safety was analyzed by Martino et al. [44, 45] 
who carried out a study to evaluate raloxifene’s safety after 8 
years of treatment in 4,011 postmenopausal women with 
osteoporosis who had been included in the CORE Study 
(Continuing Outcomes Relevant to Evista), a continuation of 
the MORE Study. The incidence of hot flashes, leg cramps, 
and peripheral edema, adverse events associated with treat-
ment with raloxifene, was not statistically significant be-
tween the different treatment groups (p > 0.5 for each event). 
Over the course of the 8 years, hot flashes and leg cramps 
were reported more frequently in the raloxifene-treated 
group than in the placebo group (p < 0.001, p = 0.008, re-
spectively), albeit such was not the case with peripheral 
edema (p = 0.24). The relative risk of thromboembolism in 
the group of patients who received raloxifene (2.9 events per 
1,000 women-years) compared to the placebo-treated group 
(1.3 events per 1,000 women-years) was 2.17 (95% CI = 
0.83 to 5.70). The incidence of venous thromboembolic 
events was 2.2 and 1.3 events per 1,000 women-years in the 
raloxifene and placebo groups, respectively. 
  Cardiovascular risks were assesed in RUTH (Raloxifene 
Use for the Heart Trial) study [46]. This was a randomized, 
double-blind, placebo-controlled, international study con-
ducted in postmenopausal women at risk for major coronary 
events. A total of 10,101 postmenopausal women with estab-
lished coronary heart disease or at increased risk for coro-
nary heart disease were randomly assigned to either placebo 
(N = 5057) or raloxifene 60 mg/day (N = 5044). Raloxifene 
treatment neither increased nor decreased the risk of coro-
nary events (533 versus 553 events; HR = 0.95; 95% CI = 
0.84-1.07). There were no significant between-group differ-
ences in the incidences of stroke, death from any cause, or 
overall death from cardiovascular causes. Women treated 
with raloxifene had higher risks of venous thromboembolic 
events (absolute risk increase, 1.2 per 1000 woman-years) 
and fatal stroke (absolute risk increase, 0.7 per 1000 woman-
years), but had lower risks of clinical vertebral, but not non-
vertebral, fractures (absolute risk reduction, 1.3 per 
1000  woman-years) and death from noncardiovascular 
causes (absolute risk reduction, 1.7 per 1000 woman-years). 
Significantly fewer women in the raloxifene group had one 
or more hospitalizations for any cause (52% vs 54%; HR = 
0.91; 95% CI = 0.87-0.96; P = 0.001). 
  Insofar as genitourinary safety is concerned, raloxifene 
did not cause endometrial hypertrophy nor increased the risk 
vaginal bleeding [27, 36]. In fact, in the clinical trials in 
which raloxifene (n = 317) was compared to continuous 
combined hormone replacement therapy (n = 110) or with 
cyclic hormone replacement therapy (n = 205), the incidence 
of breast symptoms and uterine bleeding in the women 
treated with raloxifene was significantly lower than in the 
women treated with either of the two hormone replacement 
therapy (HRT) regimens. 
  Raloxifene should not be administered to pregnant 
women or to men, since its innocuousness has not been 
demonstrated in these patients. 
APPLICABILITY IN CLINICAL TRAUMATOLOGY 
PRACTICE 
  Raloxifene had demonstrated a decreasing the risk of 
vertebral fractures in patients with postmenopausal osteopo-
rosis [25], due to its ability of slowing the accelerated bone 
turnover to premenopausal ranges; increase BMD,
 structur-
ally recover bone, and increase bone strength. In a post-hoc 
analysis, authors pointed out that in the subgroup of women 
with severe baseline vertebral fractures, raloxifene signifi-
cantly decreased the risk of subsequent nonvertebral frac-
tures [36]. Likewise, raloxifene is the first antirresorptive 
agent to demonstrate a decrease in the risk of vertebral frac-
tures in patients with osteopenia [35]. According all these 
data, raloxifene is a clearly indicated for the prevention and 
treatment of postmenopausal osteoporosis, especially in 
those cases with vertebral predominancy. 
  In addition to having demonstrated its antifracture effect, 
raloxifene presents beneficial effects on lipid metabolism 
and breast tissue. It is capable of lowering LDL-cholesterol 
levels and increasing HDL-cholesterol ones [36, 40] and it 
also appears to reduce the risk of invasive breast cancer [37, 
39]. Both effects increase the value of this drug, making it 
especially useful in women with osteopenia or postmeno-
pausal osteoporosis with lipid alterations or breast cancer 
risk factors. 
  Consequently, at a dose of 60 mg/day (that is, one tablet 
per day)  taken at any time of the day, independently of 
meals, and associated with calcium (1200-1500 mg/day) and 20    The Open Orthopaedics Journal, 2009, Volume 3  Caeiro et al. 
vitamin D3 (400 UI/day) (especially in women with a diet 
that is low in calcium), raloxifene is efficacious in the pre-
vention and treatment of postmenopausal osteoporosis, 
above all in predominantly vertebral osteoporosis, while at 
the same time, presenting a low incidence of side effects and 
exhibiting a beneficial effect on breast tissue by decreasing 
the risk of breast cancer. These characteristics make 
raloxifene a pharmacolocial alternative in our arsenal of 
treatments that would help us to treat our patients with os-
teoporosis. 
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